TITLE

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

AUTHOR(S)
De Padua Silva, L.; de Lima, M.; Kantarjian, H.; Faderl, S.; Kebriaei, P; Giralt, S.; Davisson, J.; Garcia-Manero, G.; Champlin, R.; Issa, J.-P; Ravandi, F.
PUB. DATE
June 2009
SOURCE
Bone Marrow Transplantation;Jun2009, Vol. 43 Issue 11, p839
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment with this drug before allo-SCT will increase the toxicity of the preparative regimen or otherwise affect the results of the transplant. We report the outcome of 17 patients with MDS with a median age of 55.5 years (range, 36–66 years) who underwent an allo-SCT (12 siblings, 5 unrelated) after prior therapy with decitabine. Preparative regimens consisted of fludarabine in combination with BU (n=8) or melphalan (n=9). The source of stem cells was marrow in four patients and peripheral blood (PB) in 13 patients. Thirteen patients were in CR within 100 days of transplant. With a median follow-up of 12 months (range, 3–35 months), 11 patients are alive; eight in CR and three with progressive disease. Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in MDS and should be evaluated in a prospective trial.Bone Marrow Transplantation (2009) 43, 839–843; doi:10.1038/bmt.2008.400; published online 19 January 2009
ACCESSION #
41335277

 

Related Articles

  • Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Christopeit, M; Ocheni, S; Haferlach, T; Miersch, K; Zabelina, T; Klyuchnikov, E; Binder, M; Ayuk, F; Schafhausen, P; Zander, A R; Bokemeyer, C; Kröger, N; Bacher, U // Bone Marrow Transplantation;Mar2013, Vol. 48 Issue 3, p465 

    The article presents a study which describes the disease status of bone marrow (BM) cytomorphology in patients with myelodysplastic syndromes (MDS). It describes the blast count, dysplasia, and cellularity in stem cell recipients following an allogeneic haematopoietic SCT. The study implies that...

  • Targeting Immune Dysregulation in Myelodysplastic Syndromes. Olnes, Matthew J.; Sloand, Elaine M. // JAMA: Journal of the American Medical Association;2/23/2011, Vol. 305 Issue 8, p814 

    The article describes the case of a 56-year-old woman with myelodysplastic syndrome (MDA). She complained of fatigue and easy bruising for several weeks. She became progressively anemic and leukopenic over the next five months. She was treated with granulocyte colony-stimulating factor. The...

  • Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Kröger, N; Shimoni, A; Zabelina, T; Schieder, H; Panse, J; Ayuk, F; Wolschke, C; Renges, H; Dahlke, J; Atanackovic, D; Nagler, A; Zander, A // Bone Marrow Transplantation;Feb2006, Vol. 37 Issue 4, p339 

    We investigated a dose-reduced conditioning regimen consisting of treosulfan and fludarabine followed by allogeneic stem cell transplantation (SCT) in 26 patients with secondary AML or MDS. Twenty patients were transplanted from matched or mismatched unrelated donors and six from HLA-identical...

  • Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Benesch, M.; McDonald, G. B.; Schubert, M.; Appelbaum, F. R.; Deeg, H. J. // Bone Marrow Transplantation;Dec2003, Vol. 32 Issue 11, p1071 

    Summary:The objective of this prospective study was to determine whether amifostine (Ethyol®) reduced conditioning-related toxicity following a regimen of busulfan (7?mg/kg) and fractionated total body irradiation (6 × 200?cGy). In all, 12 patients with advanced myelodysplastic syndrome...

  • Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. Yamada, Toshiki; Tsurumi, Hisashi; Kasahara, Senji; Hara, Takeshi; Sawada, Michio; Moriwaki, Hisataka // Journal of Cancer Research & Clinical Oncology;Aug2003, Vol. 129 Issue 8, p485 

    We investigated whether immunosuppressive therapy using methylprednisolone (mPSL) with or without cyclosporin A (CsA) could benefit patients with myelodysplastic syndrome (MDS). Eligibility criteria for this study were a clinical diagnosis of MDS with less than 5% blast in peripheral blood, less...

  • Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys. Sekeres, Mikkael A.; Schoonen, W. Marieke; Kantarjian, Hagop; List, Alan; Fryzek, Jon; Paquette, Ronald; Maciejewski, Jaroslaw P. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p1542 

    Background Myelodysplastic syndromes (MDS) comprise a group of pathologically and cytogenetically distinct bone marrow disorders. Little is known about the characteristics of MDS patients, including their pathological and prognostic classifications, cytopenias, transfusion and supportive care...

  • CITATIONS AND CLINICIANS' NOTES: MYELODYSPLASTIC SYNDROME.  // Current Medical Literature: Leukemia & Lymphoma;2005, Vol. 13 Issue 1, p21 

    Discusses research being done on reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab conditioning. Reference to a study by A. Y. Ho et al....

  • Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Madureira, A. B. M.; Eapen, M.; Locatelli, F.; Teira, P.; Zhang, M.-J.; Davies, S. M.; Picardi, A.; Woolfrey, A.; Chan, K.-W.; Socié, G.; Vora, A.; Bertrand, Y.; Sales-Bonfim, C. M.; Gluckman, E.; Niemeyer, C.; Rocha, V.; Socié, G; Eurocord-European Blood and Marrow Transplant Group; Center of International Blood and Marrow Transplant Registry; European Working Group on childhood MDS // Leukemia (08876924);Mar2011, Vol. 25 Issue 3, p449 

    We describe 70 children with myelodysplastic syndrome (MDS) (refractory cytopenia (n=31) and refractory anemia with excess blasts (n=30) or blasts in transformation (n=9)) who received umbilical cord blood (UCB) transplantation with a single UCB unit and a myeloablative conditioning regimen....

  • Update On Myelodysplastic Syndrome. Ho, Christine M.; Butera, James N. // Medicine & Health Rhode Island;Sep2009, Vol. 92 Issue 9, p315 

    The article offers information on myelodysplastic syndrome (MDS). The condition is a bone marrow stem cell disorder that often affects patients over 60 years old, predominant in males and Caucasians. MDS is characterized by cytopenias, bone marrow morphologic changes and cytogenetic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics